Download the 2024 full event guide to discover what attendees explored. They examined the technical developments in the identification and validation of novel epigenetic modulators, stabilizers, chromatin remodels and post-translational modification-inducing modalities for previously undrugged targets. Along with the development of first-in-class heterobifunctionals, explored the development of bispecific antibodies for improved targeted degradation and how ADCs are improving the payload of induced proximity drugs.